Boston Scientific (BSX) Stock
Key stats
- Market cap
- $61.96B
- Price / Earnings ratio
- 17.7x
- EPS (TTM)
- $2.38
- Volume
- Loading
- 52-week high
- $105.65
- 52-week low
- $39.57
- EPS vs analyst estimate
- +5.6%Q3 FY25 · $0.75 vs $0.71
Source: third-party data provider, as of November 10, 2026
EPS estimate: analyst consensus
Compare with BSX
Recent news

Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
BSX

Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
BSX

Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
BSX

Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
BSX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.62
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.00
- SMA 50
- $44.28
- Price below SMA 50
- EMA 50
- $44.70
- Price below EMA 50
- SMA 200
- $55.12
- Price below SMA 200
- EMA 200
- $58.76
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 15 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.87 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
BSX

Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
BSX

Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
BSX

Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
BSX

New Strong Sell Stocks for October 30th
New Strong Sell Stocks for October 30th
BSX

BSX Q3 Earnings Call Flags Growth Challenges Through 2027
BSX Q3 Earnings Call Flags Growth Challenges Through 2027
BSX

BSX Stock Looks To Snap 3-Week Winning Streak: Analysts Downgrade Boston Scientific As Cyberattack And Slowing Growth Cloud Outlook
BSX Stock Looks To Snap 3-Week Winning Streak: Analysts Downgrade Boston Scientific As Cyberattack And Slowing Growth Cloud Outlook
BSX

Boston Scientific Q3 Earnings Call Highlights
Boston Scientific Q3 Earnings Call Highlights
BSX

Boston Scientific: 3 Key Takeaways for Long-Term Investors
Boston Scientific: 3 Key Takeaways for Long-Term Investors
BSX

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact
Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact
BSX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for nearly 40 years, they advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of health care.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael F. Mahoney | Chairman, President & CEO | 1965 |
| Mr. Jonathan R. Monson | Executive VP & CFO | 1974 |
| Mr. Vance R. Brown J.D. | EVP, General Counsel & Corporate Secretary | 1970 |
| Mr. Joseph M. Fitzgerald | Executive VP & Group President of Cardiovascular | 1964 |
| Mr. Arthur Crosswell Butcher | Executive VP and Group President of MedSurg & Asia Pacific | 1971 |
| Mr. Paudie O'Connor | Executive Vice President of Global Operations | 1968 |
| Ms. Emily M. Woodworth | Senior VP, Global Controller & Chief Accounting Officer | 1978 |
| Mr. Adam Smith | General Manager of Global Sales & Marketing | — |
| Ms. Miriam O'sullivan | Senior VP & Chief Human Resources Officer | 1981 |
| Ms. Brenda Becker | Senior Vice President of Global Government Affairs | 1960 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 10, 2026
Technical indicators
- RSI 14
- 49.62
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.11
- MACD histogram
- 0.00
- SMA 50
- $44.28
- Price below SMA 50
- EMA 50
- $44.70
- Price below EMA 50
- SMA 200
- $55.12
- Price below SMA 200
- EMA 200
- $58.76
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst views
15 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $44.00
- Average
- $50.13
- High
- $65.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.3 | +11.4 | ||||||||||
| 2022 | -0.5 | +1.5 | +2.1 | -6.4 | -1.5 | -6.6 | +8.0 | -1.8 | -5.5 | +8.1 | +5.9 | +0.3 |
| 2023 | +0.5 | -1.7 | +6.9 | +4.8 | -2.5 | +5.0 | -3.2 | +4.0 | -1.5 | -3.1 | +8.2 | +3.0 |
| 2024 | +9.4 | +2.1 | +2.0 | +5.5 | +4.7 | +2.0 | -3.3 | +8.8 | +3.3 | -0.1 | +8.4 | -1.2 |
| 2025 | +14.5 | +0.7 | -3.8 | +1.6 | +2.0 | +3.1 | +0.1 | +0.1 | -8.5 | +5.1 | +3.0 | -5.6 |
| 2026 | -1.2 | -16.3 | -17.7 | -7.1 | -14.5 | -11.0 | +8.5 | -0.3 | -9.2 | -2.9 | -3.5 |



